CStone Pharmaceuticals represents a set of core values and a corporate philosophy that guides its operations and growth. Committed to advancing innovative therapies and transforming patients' lives, CStone Pharmaceuticals focuses on integrity, dedication, and excellence in all aspects of its business. By adhering to rigorous scientific standards and maintaining transparency, the company strives to deliver high-quality treatments and improve healthcare outcomes. CStone Pharmaceuticals prioritizes collaboration and partnerships to accelerate the development and commercialization of breakthrough therapies. With a strong emphasis on patient-centric approaches and a relentless pursuit of scientific innovation, CStone Pharmaceuticals aims to make a significant impact in the field of biopharmaceuticals.

CStone Pharmaceuticals is primarily present in China.

CStone Pharmaceuticals is a leading biopharmaceutical company that has achieved several significant milestones. The company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange in 2019, raising substantial capital for its operations. CStone Pharmaceuticals also entered into strategic collaborations with global pharmaceutical companies like Pfizer and Bayer, enhancing its research and development capabilities. Furthermore, the company received approval for its first-in-class drug, CS1001, from the National Medical Products Administration in China, marking a major breakthrough in the field of immuno-oncology. With these accomplishments, CStone Pharmaceuticals has demonstrated its commitment to advancing innovative treatments for patients worldwide.

CStone Pharmaceuticals is a leading biopharmaceutical company specializing in the development and commercialization of innovative immunotherapies and precision medicine to serve patients with cancer. Founded in 2015, CStone is headquartered in Suzhou, China, with global operations and collaborations to advance the treatment landscape for patients globally. The company focuses on developing first-in-class and best-in-class therapies that target multiple tumor types, including globally unmet medical needs. With a strong pipeline of potential drug candidates and a commitment to research and development, CStone Pharmaceuticals aims to make a meaningful impact on the lives of cancer patients worldwide.

The main competitors of CStone Pharmaceuticals in the market include companies such as BeiGene, Innovent Biologics, Jiangsu Hengrui Medicine, and Hutchison China MediTech.

CStone Pharmaceuticals is primarily active in the biopharmaceutical industry.

CStone Pharmaceuticals follows a strategic business model focused on developing and commercializing innovative immunotherapies to address unmet medical needs. As a leading biopharmaceutical company in China, CStone concentrates on researching and producing novel, first-in-class oncology therapeutics. Leveraging collaborations, CStone invests in clinical development, regulatory filings, and commercialization activities, aiming to deliver transformative medicines to cancer patients. By combining internal R&D capabilities with partnerships, CStone targets various cancer indications, including lung, liver, colorectal, and gastric cancers, among others. With a commitment to improving patient outcomes, CStone Pharmaceuticals is dedicated to advancing the field of oncology through cutting-edge therapies.

Det CStone Pharmaceuticals P/E-forhold er -6,06.

CStone Pharmaceuticals KUV er 2,22.

AlleAktien Kvalitetsscore for CStone Pharmaceuticals er 2/10.

Den forventede CStone Pharmaceuticals omsætning er 675,04 mio. CNY.

Den forventede CStone Pharmaceuticals indtjening er -247,16 mio. CNY.

CStone Pharmaceuticals is a leading biotechnology company focused on the development and marketing of innovative cancer drugs. The company was founded in 2015 and is headquartered in Suzhou, China, operating globally. CStone Pharmaceuticals aims to develop new cancer drug candidates and market them in collaboration with established partners. The company works to address the need for drugs in oncology, immunology, autoimmunity, and connective tissue to maximize treatment options. The company has a broad pipeline, including various products such as CS1001, a PD-L1 antibody; CS1002, an anti-CD38 antibody used for the treatment of multiple myeloma and other malignant diseases; and CS3006, a tyrosine kinase inhibitor (TKI) that acts against cancer diseases like lung and breast cancer. CStone Pharmaceuticals has also agreed to collaborate with Pfizer to jointly develop CS1003, an anti-PD-1 antibody, and CS2006, an anti-CTLA4 antibody. This partnership aims to leverage the strengths of both companies and accelerate product development at a fast pace. The company maintains strong partnerships with various firms such as Blueprint Medicines, Agios Pharma, and others to promote innovative cancer drug candidates. Additionally, it collaborates closely with leading academic institutions and research facilities to develop new therapy options. CStone Pharmaceuticals also offers clinical trials to investigate the safety and efficacy of its drugs. The clinical studies aim to support FDA and European regulatory authorities in bringing the drugs to market. The company has ambitious plans to grow and achieve a leading position in cancer drug development and marketing in the future. CStone Pharmaceuticals is working to expand its product diversity and pipeline to meet the needs of patients. Simultaneously, the company will continue to expand partnerships with other companies and research institutions to develop innovative therapies and expand in the field of cancer drugs. Overall, CStone Pharmaceuticals' business model is focused on the development, marketing, and sale of innovative cancer drugs. The company relies on a broad pipeline and strong partnerships to achieve its vision and become one of the leading forces in the oncology industry, particularly in the Chinese market.

CStone Pharmaceuticals udbetaler et udbytte på 0 CNY fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for CStone Pharmaceuticals, eller selskabet udbetaler ikke udbytte.

ISIN'en for CStone Pharmaceuticals er KYG2588M1006.

WKN for CStone Pharmaceuticals er A2PEFW.

Tickeren for CStone Pharmaceuticals er 2616.HK.

I løbet af de sidste 12 måneder betalte CStone Pharmaceuticals en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil CStone Pharmaceuticals sandsynligvis betale en dividende på 0 CNY.

Udbytteafkastet for CStone Pharmaceuticals er i øjeblikket .

CStone Pharmaceuticals betaler kvartalsvis udbytte. Dette uddeles i månederne .

CStone Pharmaceuticals betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 CNY. Dette svarer til et dividendeafkast på 0 %.

CStone Pharmaceuticals bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på CStone Pharmaceuticals fra den 3.8.2024 på 0 CNY, skulle du have haft aktien i din portefølje før ex-datoen den 3.8.2024.

Udbetalingen af det sidste udbytte blev foretaget den 3.8.2024.

I løbet af 2023 udbetalte CStone Pharmaceuticals 0 CNY i form af dividender.

Udbytterne fra CStone Pharmaceuticals udbetales i CNY.